Thérapies de Conversion

Pratiques visant à modifier l'orientation sexuelle ou l'identité de genre, illégales en France depuis la loi n°2022-92, et leurs effets psychologiques documentés.

500 articles disponibles

conversion therapy
sexual orientation change effort
SOCE harm
gender identity conversion
reparative therapy mental health
ex-gay therapy
conversion practice religious

Conversion practices in Aotearoa New Zealand: Developing a holistic response to spiritual abuse.

Research arising from conversion practices, also known as conversion therapy and sexual orientation and gender identity change efforts, has generally been underpinned by an emancipatory discourse that…

Trauma Psychologique Religieux Abus Spirituels et Emprise Religieuse Thérapies de Conversion
Roguski, M., & Atwool, N. (2024). Conversion practices in Aotearoa New Zealand: Developing a holistic response to spiritual abuse.. PLoS One, 19(5), e0302163. https://doi.org/10.1371/journal.pone.0302163

A case report of a patient with stage IIIa hepatocellular carcinoma complicated by early gastric cancer.

We report a case of patient with Stage IIIa Hepatocellular Carcinoma Complicated by Early Gastric Cancer. Although Stage IIIa liver cancer can be treated with surgery, the overall prognosis of surgery…

Thérapies de Conversion
Song, X., Cai, R., Wang, L., Ding, F., & Ni, H. (2024). A case report of a patient with stage IIIa hepatocellular carcinoma complicated by early gastric cancer.. Front Oncol, 14, 1440171. https://doi.org/10.3389/fonc.2024.1440171

Sarcomatoid carcinoma transformation in oral undifferentiated carcinoma following sequential immune combined targeted therapy: a case report.

The diagnosis and treatment of head and neck undifferentiated carcinoma (HNUC) present significant challenges. Herein, we present the case of a patient with advanced HNUC who underwent conversion surg…

Thérapies de Conversion
Li, J., Zhan, X., Shang, W., & Song, K. (2024). Sarcomatoid carcinoma transformation in oral undifferentiated carcinoma following sequential immune combined targeted therapy: a case report.. Front Immunol, 15, 1484915. https://doi.org/10.3389/fimmu.2024.1484915

Case report: Successful radical surgery following complete pathological remission of advanced HCC with Tislelizumab/Lenvatinib plus TACE.

The combination therapy of Tislelizumab plus Lenvatinib has recently emerged as the new standard of care for unresectable hepatocellular carcinoma (HCC). This treatment has demonstrated a significant …

Thérapies de Conversion
Xie, Y., Lyu, T., Zou, Y., & Wang, J. (2024). Case report: Successful radical surgery following complete pathological remission of advanced HCC with Tislelizumab/Lenvatinib plus TACE.. Front Oncol, 14, 1369567. https://doi.org/10.3389/fonc.2024.1369567

"Ethical Care in Secret": Qualitative Data from an International Survey of Exploratory Therapists Working with Gender-Questioning Clients.

This is a mixed methods international survey of therapists ( = 89) belonging to Therapy First, an organization supporting the use of exploratory therapy, rather than gender affirmative therapy, with g…

Thérapies de Conversion
Jenkins, P., & Panozzo, D. (2024). "Ethical Care in Secret": Qualitative Data from an International Survey of Exploratory Therapists Working with Gender-Questioning Clients.. J Sex Marital Ther, 50(5), 557-582. https://doi.org/10.1080/0092623X.2024.2329761

Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence.

BACKGROUND: Hepatic artery infusion chemotherapy (HAI) has been proposed as a valuable adjunct for multimodal therapy of primary and secondary liver malignancies. This review provides an overview of t…

Thérapies de Conversion
Kuemmerli, C., Hess, V., Dutkowski, P., Sinz, S., Kessler, U., Hess, G. F., Billeter, A. T., MĂĽller-Stich, B. P., Kollmar, O., & MĂĽller, P. C. (2024). Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence.. Pharmacology, 109(2), 86-97. https://doi.org/10.1159/000537887

Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature.

Immunotherapy has demonstrated a role in the therapeutic landscape of a small subset of patients with colorectal carcinoma (CRC) that harbor a microsatellite instability (MSI-H) status due to a defici…

Thérapies de Conversion
San-Román-Gil, M., Martínez-Delfrade, I., Albarrán-Fernández, V., Guerrero-Serrano, P., Pozas-Pérez, J., Chamorro-Pérez, J., Rosero-Rodríguez, D., Sotoca-Rubio, P., Barrill-Corpa, A. M., Alia-Navarro, V., González-Merino, C., García-de-Quevedo-Suero, C., López, V., Ruz-Caracuel, I., Perna-Monroy, C., & Ferreiro-Monteagudo, R. (2024). Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature.. Front Immunol, 15, 1352262. https://doi.org/10.3389/fimmu.2024.1352262

Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.

BACKGROUND: The synergistic effect of locoregional therapy in combination with systemic therapy as a conversion therapy for unresectable hepatocellular carcinoma (uHCC) is unclear. The purpose of this…

Thérapies de Conversion
Wu, X. K., Yang, L. F., Chen, Y. F., Chen, Z. W., Lu, H., Shen, X. Y., Chi, M. H., Wang, L., Zhang, H., Chen, J. F., Huang, J. Y., Zeng, Y. Y., Yan, M. L., & Zhang, Z. B. (2024). Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.. EClinicalMedicine, 67, 102367. https://doi.org/10.1016/j.eclinm.2023.102367

Review of two immunosuppressants: tacrolimus and cyclosporine.

Immunosuppressants are vital in organ transplantation including facial transplantation (FT) but are associated with persistent side effects. This review article was prepared to compare the two most us…

Thérapies de Conversion
Lee, H., Myoung, H., & Kim, S. M. (2023). Review of two immunosuppressants: tacrolimus and cyclosporine.. J Korean Assoc Oral Maxillofac Surg, 49(6), 311-323. https://doi.org/10.5125/jkaoms.2023.49.6.311

Oligometastatic Gastric Cancer: Clinical Data from the Meta-Gastro Prospective Register of the Italian Research Group on Gastric Cancer.

BACKGROUND: Interest in the field of metastatic gastric cancer has grown in recent years, and the identification of oligometastatic patients plays a critical role as it consents to their inclusion in …

Thérapies de Conversion
Bencivenga, M., Ministrini, S., Morgagni, P., Mura, G., Marrelli, D., Milandri, C., Mazzei, M. A., Berselli, M., Monti, M., Graziosi, L., Reddavid, R., Rosa, F., Solaini, L., Donini, A., Fumagalli, R. o. m. a. r. i. o. . U., Roviello, F., de, M. a. n. z. o. n. i. . G., & Tiberio, G. A. M. (2023). Oligometastatic Gastric Cancer: Clinical Data from the Meta-Gastro Prospective Register of the Italian Research Group on Gastric Cancer.. Cancers (Basel), 16(1). https://doi.org/10.3390/cancers16010170

PD-L1 inhibitor plus gemcitabine and cisplatin therapy followed by conversion surgery for initially unresectable advanced gallbladder cancer.

Advanced gallbladder cancer (GBC) is not amenable to surgical resection. There are limited treatment options and the prognosis is dismal. The role of immune checkpoint inhibitors in conversion therapy…

Thérapies de Conversion
Zhang, S., Nie, J., Tai, S., & Zheng, T. (2023). PD-L1 inhibitor plus gemcitabine and cisplatin therapy followed by conversion surgery for initially unresectable advanced gallbladder cancer.. BMJ Case Rep, 16(12). https://doi.org/10.1136/bcr-2023-255403

Chinese expert consensus on the overall management of liver function in conversion therapy for liver cancer (2022 edition).

Thérapies de Conversion
Meng, Q., Yang, Z., Zhu, Z., Li, J., Bi, X., Chen, X., Hao, C., Huang, Z., Li, F., Li, X., Li, G., Yang, Y., Zhang, Y., Zhao, H., Zhao, H., Zhu, X., Zhu, J., Cai, J., Liver, T. u. m. o. r. . B. r. a. n. c. h. . o. f. . t. h. e. . C. h. i. n. a. . I. n. t. e. r. n. a. t. i. o. n. a. l. . E. x. c. h. a. n. g. e. . a. n. d. . P. r. o. m. o. t. i. v. e. . A. s. s. o. c. i. a. t. i. o. n. . f. o. r. . M. e. d. i. c. a. l. . a. n. d. . H. e. a. l. t. h. c. a. r. e. . (. C. P. A. M. )., … Liver, C. a. n. c. e. r. . P. r. o. f. e. s. s. i. o. n. a. l. . C. o. m. m. i. t. t. e. e. . o. f. . C. h. i. n. e. s. e. . M. e. d. i. c. a. l. . D. o. c. t. o. r. . A. s. s. o. c. i. a. t. i. o. n. (2023). Chinese expert consensus on the overall management of liver function in conversion therapy for liver cancer (2022 edition).. Chin Med J (Engl), 136(24), 2909-2911. https://doi.org/10.1097/CM9.0000000000002950